12. Female subject is eligible to enter and participate in the study if she is of a. Non-childbearing potential b. Childbearing potential and has a negative screening serum pregnancy test (within 3 days before the first dose of BGB-A317), not be breastfeeding, and agrees to use adequate contraception during the study treatment period and for at least 120 days after the last dose of BGB-A317. Adequate contraception, when used consistently and in accordance with both the product label and instructions of the physician.